[Pharmacokinetic and clinical studies of flomoxef in the perinatal period].
Pharmacokinetic and clinical studies on flomoxef (FMOX) in the perinatal period were carried out and following results were obtained 1. The pharmacokinetic parameter T1/2's of FMOX in maternal serum, umbilical cord serum and amniotic fluid in mothers after single intravenous injection of 1 g (n = 46) and 2 g (n = 34) were 1.11, 9.24, 9.24 hours and 2.54, 12.49, 12.49 hours, respectively. Cmax's and Tmax's of umbilical cord serum and amniotic fluid were 12.71, 11.77 micrograms/ml and 0.57, 3.35 hours upon single dose of 1 g i.v., and 35.17, 12.37 micrograms/ml and 0.32, 3.42 hours upon single dose of 2 g i.v., respectively. 2. Clinical usefulness were evaluated in 93 cases including were various infections in pregnancy and puerperal period. In pregnancy cases, clinical efficacy rate was 95.5% (21/22), and 100% in puerperal period. Bacteriological response rate was 84.6% (eradicated: 29, decreased: 4, unchanged: 2, replaced: 4 and unknown: 8 cases). No severe side effects nor clinical laboratory test results were observed in any cases. From above basic and clinical results, we conclude that FMOX is a useful and safe agent for various infections in pregnancy and puerperal period.
Department of Obstetrics and Gynecology, Juntendo University School of Medicine.
S
S
Matsuda
H
H
Hirayama
K
K
Oh
K
K
Tamate
K
K
Sengoku
M
M
Ishikawa
T
T
Shimizu
H
H
Haga
T
T
Hasegawa
H
H
Takada
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002585:Cesarean Section; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism; D011292:Premedication
D002511:Cephalosporins; C045693:flomoxef